Q2 EPS Estimate for Tarsus Pharmaceuticals Lifted by Analyst

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Lifesci Capital increased their Q2 2026 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued on Tuesday, March 24th. Lifesci Capital analyst F. Brisebois now expects that the company will earn ($0.01) per share for the quarter, up from their prior estimate of ($0.36). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ FY2026 earnings at ($0.66) EPS.

Several other analysts have also recently issued reports on TARS. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. The Goldman Sachs Group reissued a “neutral” rating and set a $68.00 price target on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Barclays initiated coverage on shares of Tarsus Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $100.00 price objective for the company. Oppenheimer raised their price objective on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Finally, Zacks Research downgraded shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.83.

Tarsus Pharmaceuticals Price Performance

NASDAQ:TARS opened at $66.96 on Thursday. Tarsus Pharmaceuticals has a one year low of $38.51 and a one year high of $85.25. The stock has a market cap of $2.85 billion, a PE ratio of -41.33 and a beta of 0.55. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85. The stock has a 50 day moving average price of $68.47 and a 200 day moving average price of $70.45.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $151.67 million for the quarter, compared to analyst estimates of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, Director William J. Phd Link sold 12,500 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $68.79, for a total transaction of $859,875.00. Following the sale, the director directly owned 116,332 shares in the company, valued at $8,002,478.28. This represents a 9.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Bryan Wahl sold 4,231 shares of the business’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $283,477.00. Following the completion of the transaction, the general counsel owned 63,959 shares of the company’s stock, valued at approximately $4,285,253. This trade represents a 6.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 79,391 shares of company stock worth $5,432,035 in the last 90 days. Insiders own 8.97% of the company’s stock.

Institutional Trading of Tarsus Pharmaceuticals

Several hedge funds have recently modified their holdings of TARS. Comerica Bank grew its stake in Tarsus Pharmaceuticals by 470.0% during the 4th quarter. Comerica Bank now owns 855 shares of the company’s stock worth $70,000 after purchasing an additional 705 shares in the last quarter. Truvestments Capital LLC raised its position in Tarsus Pharmaceuticals by 106.1% in the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after purchasing an additional 468 shares in the last quarter. Rockefeller Capital Management L.P. raised its position in Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after purchasing an additional 172 shares in the last quarter. Osaic Holdings Inc. boosted its stake in shares of Tarsus Pharmaceuticals by 779.1% in the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after buying an additional 2,462 shares during the period. Finally, Leonteq Securities AG purchased a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at about $164,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.